ResApp Health Limited announced that health technology company Ilara Health will promote, market and sell ResAppDx, ResApp's smartphone app for acute respiratory disease. Ilara Health powers existing primary care facilities with next-generation point of care diagnostic tools to bridge the diagnostic gap across sub-Saharan Africa. Ilara are currently partnered with over 250 clinics across the four large cities in Kenya and will look to expand across the wide country and a new African market within the next 12 months. R esAppDx is ResApp's acute respiratory diagnostic test that uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. It is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia. ResAppDx is also approved as a medical device in Kenya.